Disease · MONDO_0005089
Comparisons in its trials31
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 31
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Phase II - Analysis Group 2 MLN0128 vs Phase II - Analysis Group 2 Pazopanib: Number of Patients Having CR, PR, or SD at 6 Months (Phase II Analysis Group 2 - Initial Treatment Period) | 1 of 56 | 5 of 58 | 114 | NCT02601209 | Trial comparisons |
| Phase II - Analysis Group 2 MLN0128 vs Phase II - Analysis Group 2 Pazopanib: The Number of Patients Who Experienced Grade 3+ Adverse Events (Phase II Analysis Group 2 - Initial Treatment Period) | 28 of 55 | 38 of 56 | 111 | NCT02601209 | Trial comparisons |
| Gemcitabine, Docetaxel, Bevacizumab vs Gemcitabine, Docetaxel, Placebo: serious adverse events | 12 of 37 | 6 of 10 | 47 | NCT00887809 | Trial comparisons |
| Docetaxel + Gemcitabine + Pegfilgrastim + Vorinostat 300 mg/Day vs Docetaxel + Gemcitabine + Pegfilgrastim + Vorinostat 200 mg Twice/Day: deaths from any cause | 26 of 31 | 5 of 6 | 37 | NCT01879085 | Trial comparisons |
| Docetaxel + Gemcitabine + Pegfilgrastim + Vorinostat 300 mg/Day vs Docetaxel + Gemcitabine + Pegfilgrastim + Vorinostat 200 mg Twice/Day: serious adverse events | 19 of 31 | 3 of 6 | 37 | NCT01879085 | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | 10 of 16 | 5 of 13 | 29 | NCT04076579 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 2 of 16 | 4 of 13 | 29 | NCT04076579 | Trial comparisons |
| Cohort 1 vs Cohort 2: Overall Response Rate | 0 of 16 | 2 of 12 | 28 | NCT04076579 | Trial comparisons |
| Cohort 1/Vaccine Plus Chemotherapy vs Cohort 2/Vaccine Alone: Number of Participants With an Immunologic Responses | 4 of 10 | 4 of 11 | 21 | NCT02054104 | Trial comparisons |
Cohort 1/Vaccine Plus Chemotherapy vs Cohort 2/Vaccine Alone: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 8 of 10 | 6 of 11 | 21 | NCT02054104 | Trial comparisons |
| Cohort 1/Vaccine Plus Chemotherapy vs Cohort 2/Vaccine Alone: deaths from any cause | 0 of 10 | 0 of 11 | 21 | NCT02054104 | Trial comparisons |
| Cohort 1/Vaccine Plus Chemotherapy vs Cohort 2/Vaccine Alone: serious adverse events | 0 of 10 | 0 of 11 | 21 | NCT02054104 | Trial comparisons |
| Optional GCSF vs Mandatory GCSF: Rate of Progression-free Survival at 6 Months in Participants Who Received PCI-24781/Doxorubicin Combination Administration. | 1 of 6 | 6 of 14 | 20 | NCT01027910 | Trial comparisons |
| Optional GCSF vs Mandatory GCSF: Number of Partial Responses (PR) | 0 of 6 | 3 of 14 | 20 | NCT01027910 | Trial comparisons |
| Optional GCSF vs Mandatory GCSF: Dose Limiting Toxicities | 2 of 6 | 2 of 14 | 20 | NCT01027910 | Trial comparisons |
| PCI-24781+Dox Without Mandated GCSF vs PCI-24781+Dox With Mandated GCSF: serious adverse events | 2 of 6 | 2 of 14 | 20 | NCT01027910 | Trial comparisons |
| Phase 1: 40 mg Cabozantinib S-malate, Radiation Therapy vs Phase 1: 60 mg Cabozantinib S-malate, Radiation Therapy: deaths from any cause | 1 of 3 | 0 of 3 | 6 | NCT04220229 | Trial comparisons |
| Phase 1: 40 mg Cabozantinib S-malate, Radiation Therapy vs Phase 1: 60 mg Cabozantinib S-malate, Radiation Therapy: serious adverse events | 0 of 3 | 0 of 3 | 6 | NCT04220229 | Trial comparisons |
| Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg vs Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg: Number of Participants Who Had a Dose Limiting Toxicity (DLT) | 0 of 2 | 0 of 3 | 5 | NCT02192541 | Trial comparisons |
Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg vs Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg: Number of Participants With Serious and Non-serious Adverse Events Regardless of Attribution Assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v4.0 | 2 of 2 | 3 of 3 | 5 | NCT02192541 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005089/comparisons